CA2182213A1 - Formulation orale comprenant des particules magnetiques - Google Patents

Formulation orale comprenant des particules magnetiques

Info

Publication number
CA2182213A1
CA2182213A1 CA 2182213 CA2182213A CA2182213A1 CA 2182213 A1 CA2182213 A1 CA 2182213A1 CA 2182213 CA2182213 CA 2182213 CA 2182213 A CA2182213 A CA 2182213A CA 2182213 A1 CA2182213 A1 CA 2182213A1
Authority
CA
Canada
Prior art keywords
particles
viscosity
composition
magnetically responsive
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2182213
Other languages
English (en)
Inventor
William George Gorman
Fred Andrew Carroll
Kevin Darryl Ostrander
William Hunke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2182213A1 publication Critical patent/CA2182213A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention se rapporte à un véhicule de faible viscosité, sensiblement hydraté, utilisé pour disperser des particules magnétiquement sensibles. L'invention se rapporte également à des milieux de contraste utilisés pour visualiser, par résonance magnétique nucléaire, le système gastrointestinal en vue d'une administration orale ou rectale. Un procédé générant une image par résonance magnétique à l'aide de la composition de l'invention est également décrit.
CA 2182213 1994-01-28 1995-01-30 Formulation orale comprenant des particules magnetiques Abandoned CA2182213A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18851294A 1994-01-28 1994-01-28
US08/188,512 1994-01-28

Publications (1)

Publication Number Publication Date
CA2182213A1 true CA2182213A1 (fr) 1995-08-03

Family

ID=22693469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2182213 Abandoned CA2182213A1 (fr) 1994-01-28 1995-01-30 Formulation orale comprenant des particules magnetiques

Country Status (7)

Country Link
EP (1) EP0741581A1 (fr)
JP (1) JPH09510698A (fr)
CN (1) CN1142191A (fr)
AU (1) AU1464595A (fr)
CA (1) CA2182213A1 (fr)
MX (1) MX9603001A (fr)
WO (1) WO1995020405A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253041A1 (en) * 2000-03-31 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Dendrimer composition for magnetic resonance analysis
BR0214314A (pt) * 2001-11-21 2004-11-09 E Z Em Inc Formulações para uso em procedimentos médicos ou de diagnóstico
BRPI0414438A (pt) * 2003-09-18 2006-11-14 Fmc Corp método para preparar uma dispersão estável de óxido de metal em água, e, composição
JP2010518915A (ja) * 2007-02-15 2010-06-03 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 磁性粒子画像化をする構成、磁性粒子に影響を与える方法、及び／又は磁性粒子を検出する方法
US20210299284A1 (en) * 2018-08-09 2021-09-30 The Regents Of The University Of California Method and material to acquire magnetic resonance imaging data
CN113069129B (zh) * 2021-02-26 2023-04-11 四川省肿瘤医院 一种18f-fdg pet/ct检查去除胃内伪影的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615879A (en) * 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
PT81498B (pt) * 1984-11-23 1987-12-30 Schering Ag Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas
GB8916780D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
GB8916782D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
AU652804B2 (en) * 1991-01-19 1994-09-08 Meito Sangyo Kabushiki Kaisha Composition containing ultrafine particles of magnetic metal oxide
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients

Also Published As

Publication number Publication date
EP0741581A1 (fr) 1996-11-13
JPH09510698A (ja) 1997-10-28
MX9603001A (es) 1997-06-28
WO1995020405A1 (fr) 1995-08-03
CN1142191A (zh) 1997-02-05
AU1464595A (en) 1995-08-15

Similar Documents

Publication Publication Date Title
US5792445A (en) Polymers and copolymers of acrylic acid MRI of the digestive tract of patients
US4863715A (en) Method of NMK imaging using a contrast agent comprising particles of a ferromagnetic material
Rinck et al. Oral magnetic particles in MR imaging of the abdomen and pelvis.
EP0414287B1 (fr) Agent de contraste particulaire
DE69006415T2 (de) Kontrastmittelzusammensetzung.
Rijcken et al. Intraluminal contrast agents for MR imaging of the abdomen and pelvis
CA2182213A1 (fr) Formulation orale comprenant des particules magnetiques
US5393525A (en) Contrast medium comprising superparamagnetic or ferromagnetic particles capable of increasing viscosity after administration
Rubin et al. Formulation of radiographically detectable gastrointestinal contrast agents for magnetic resonance imaging: effects of a barium sulfate additive on MR contrast agent effectiveness
EP0669135A1 (fr) Preparation granulaire destinee a l'irm
Rubin et al. Liquid oral magnetic particles as a gastrointestinal contrast agent for MR imaging: efficacy in vivo
Lönnemark et al. Oral superparamagnetic particles for magnetic resonance imaging: effect in plain and viscous aqueous suspensions
Rubin et al. Methods for the systematic investigation of gastrointestinal contrast media for MRI: evaluation of intestinal distribution by radiographic monitoring

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead